Bexorg Completes $23M Series A Bringing Total Funding to $42.5M

2 minute read | October.22.2025

Bexorg, a clinical-stage biotech pioneering therapies for central nervous system (CNS) disorders, has completed a $23 million Series A financing, bringing its total funding to $42.5 million, to advance its platform and pipeline of novel therapeutics.

Orrick advised Bexorg on the round, led by Engine Ventures with support from Amplify Partners, Starbloom Capital, Connecticut Innovations and E1 Ventures.

THE COMPANY

Bexorg leverages proprietary technology to accelerate the discovery and development of innovative CNS treatments, aiming to improve outcomes for patients with complex neurological conditions.

THE IMPACT

Proceeds from the financing will enable Bexorg to expand and optimize its AI engine trained on clinically predictive whole-human brain data. The investment will accelerate clinical development and advance CNS discovery and development programs through partners and in-licensed assets, ultimately bringing innovative therapies to patients.

THE TEAM

The team was led by Mark Solakian and Jake Gatof and includes Rozman Lynch and Michelle Dold.

LEARN MORE

Related Lawyers

Mark Solakian Partner, Life Sciences & HealthTech, Technology Companies Group

Boston

See my bio

D:+1 617 880 2229
E: [email protected]

Practice:

Technology & Innovation Sector
Life Sciences & HealthTech
Technology Companies Group
Mergers & Acquisitions

vCard

See full bio

Mark Solakian Partner

Boston

With more than three decades of experience advising both private and public companies—and having served as a senior in-house executive across multiple pioneering biotech and life sciences companies—Mark brings a uniquely business minded perspective to his counsel and delivers a rare blend of legal acumen and executive experience that positions him as a trusted strategic partner to entrepreneurs, companies and investors.

Mark is a veteran of hundreds of successful venture capital financings, technology and licensing transactions, strategic alliances, corporate governance matters, mergers and acquisitions, and public and private equity and debt offerings on behalf of companies in every health and biotech related vertical.

Before joining Orrick, Mark was a partner and co-founder of the Wilson Sonsini Boston office. He previously held senior executive roles at Affymetrix (AFFX), Helicos Biosciences (HLCS) and Joule Global Holdings, where he oversaw legal strategy, led public offerings and financings, negotiated strategic partnerships and licensing transactions, and managed critical business functions including HR, finance, and government affairs.

Mark and his wife, Christine, have been married for more than 25 years and have two adult children.

Jake Gatof Partner, Technology Companies Group, Life Sciences & HealthTech

Boston

See my bio

D:+1 617 880 2228
E: [email protected]

Practice:

Technology & Innovation Sector
Technology Companies Group
Life Sciences & HealthTech

vCard

See full bio

Jake Gatof Partner

Boston

Jake counsels visionary founders and top-tier venture and growth equity funds on venture financings, complex M&A, corporate governance, strategic collaborations, and other mission-critical transactions. Known for his steady counsel and deep market knowledge, Jake helps emerging companies scale with confidence and investors deploy capital with clarity.

Jake’s experience also includes representation of top growth equity and venture capital funds in the execution of their deals and deployment of capital, including work with TPG Capital, 5AM Ventures, and Pillar VC, among others.

He is currently a member of the Board of Trustees for the Leukemia and Lymphoma Society (New England) and is an active member of the Boston venture and emerging company ecosystem, including frequent speaking engagements for founders and other stakeholders on entrepreneurship, capital formation, and strategic transaction matters.

Prior to joining Orrick, Jake worked with Wilson Sonsini Goodrich & Rosati in its Boston office upon its founding. He lives in Boston with his wife Emily, an oncologist here in Boston, and their daughter Mia.

Rozman Lynch Managing Associate

Washington, D.C.

See my bio

D:+1 202 339 8424
E: [email protected]

vCard

See full bio

Rozman Lynch Managing Associate

Washington, D.C.

Roz focuses on representing high growth technology, life sciences and energy companies at every stage of their business life cycle. He advises on a broad range of transactional and corporate matters, starting with initial formation and through to exits, including incorporation, governance matters, venture financings and M&A transactions. Roz also advises venture capital firms and other strategic investors.

Before joining Orrick, Roz worked with Wilson Sonsini Goodrich & Rosati in its Boston office.

Michelle Dold Associate

San Francisco

See my bio

D:+1 415 773 4538
E: [email protected]

vCard

See full bio

Michelle Dold Associate

San Francisco

Michelle advises companies throughout their lifecycle, including at formation, on matters concerning corporate and securities law, fundraises, scaling and corporate governance. In addition to representing companies and entrepreneurs, Michelle advises investors on strategies to maximize the impact of their investments and represents funds in connection with their investments in private companies.

Before practicing law and joining Orrick, Michelle managed grant programs at an impact investment fund manager focused on microfinance and sustainable agriculture in emerging markets.